Biologics sales grew at an incredible rate during the past 18 months, especially when compared with pharmaceuticals. But with pressure on pricing and biosimilars looming, how long will it be until biologics' last hurrah?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Reducing effect of insulin resistance on alpha-synuclein gene expression in skeletal muscle
Diabetology & Metabolic Syndrome Open Access 02 December 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anonymous. Biosimilar legislation state by state. Nat. Biotechnol. 31, 947 (2013).
Aggarwal, S. What's fueling the biotech engine? Nat. Biotechnol. 25, 1097–1104 (2007).
Aggarwal, S. What's fueling the biotech engine—2009 to 2010. Nat. Biotechnol. 28, 1165–1171 (2010).
Aggarwal, S. What's fueling the biotech engine—2010 to 2011. Nat. Biotechnol. 29, 1083–1089 (2011).
Aggarwal, S.R. What's fueling the biotech engine—2011 to 2012. Nat. Biotechnol. 30, 1191–1197 (2012).
Aggarwal, S. What's fueling the biotech engine—2008. Nat. Biotechnol. 27, 987–993 (2009).
Aggarwal, S. What's fueling the biotech engine—2007. Nat. Biotechnol. 26, 1227–1233 (2008).
Anonymous. Building a wall against biosimilars. Nat. Biotechnol. 31, 264 (2013).
Anonymous. Bevacizumab is the first agent to significantly improve survival in recurrent cervical cancer. ASCO Daily News (4 June 2013).
Gabay, C. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381, 1541–1550 (2013).
Griffiths, C.E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118–128 (2010).
Fellner, C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. PT 37, 503–530 (2012).
Fox, J.L. Anthrax drug first antibacterial mAb to win approval. Nat. Biotechnol. 31, 8 (2013).
Pratley, R.E. et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375, 1447–1456 (2010).
Volovat, C. et al. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. Clin. Breast Cancer (in the press) (2013).
Bach, P.B., Saltz, L.B. & Wittes, R.E. In cancer care, cost matters. The New York Times (12 October 2012).
Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121, 4439–4442 (2013).
Powell, J.S. et al. Phase 3 Study of recombinant factor IX Fc fusion protein in hemophilia B. N. Engl. J. Med. doi:10.1056/NEJMoa1305074 (4 December 2013).
Anonymous. Failure to launch. Nat. Biotechnol. 31, 1 (2013).
Novel Health Strategies United States Health Care Reform Act 2014-2020, (2013).
Acknowledgements
The author thanks Novel Health Strategies, the Institute for Global Policy Research, the American Society of Clinical Oncology, the American College of Rheumatology, the American Association of Liver Diseases, American Heart Association, the American Society of Hematology and the Biotechnology Industry Association for providing support for this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
(Rob) Aggarwal, S. What's fueling the biotech engine—2012 to 2013. Nat Biotechnol 32, 32–39 (2014). https://doi.org/10.1038/nbt.2794
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2794
This article is cited by
-
Utility of High Resolution 2D NMR Fingerprinting in Assessing Viscosity of Therapeutic Monoclonal Antibodies
Pharmaceutical Research (2022)
-
Establishment of serum-free adapted Chinese hamster ovary cells with double knockout of GDP-mannose-4,6-dehydratase and GDP-fucose transporter
Cytotechnology (2022)
-
Reducing effect of insulin resistance on alpha-synuclein gene expression in skeletal muscle
Diabetology & Metabolic Syndrome (2019)
-
Insight into the roles of tyrosine on rCHO cell performance in fed-batch cultures
Applied Microbiology and Biotechnology (2019)
-
Bioprocess development of a stable FUT8−/−-CHO cell line to produce defucosylated anti-HER2 antibody
Bioprocess and Biosystems Engineering (2019)